News

October 31, 2016

Results Reported on Phase 2 Trial of Nolasiban for Pregnancy, Live Birth Rate Improvement

News

ObsEva announced that its Phase 2 clinical trial of nolasiban (OBE001) to improve clinical pregnancy and rates of live birth in women undergoing embryo transfer after in vitro fertilization (IVF) or ... Read more

October 28, 2016

Psychotherapy with Somatosensory Stimulation Can Reduce Endometriosis-associated Pain, Study Suggests

News

Psychotherapy with somatosensory stimulation can reduce global pain, pelvic pain, and difficulty in defecating, and improve quality of life in patients with endometriosis, according to a study published in the ... Read more

October 26, 2016October 26, 2016

Early Progesterone Treatment May Delay Progression of Endometriosis

News

Early treatment with the female sex hormone progesterone could delay the progression of endometriosis according to a study conducted on female mice.

October 24, 2016October 25, 2016

Cancer Antigen 125 as Diagnostic Test for Endometriosis Questioned

News

Researchers determined that cancer antigen 125 (CA 125) could be a good test for endometriosis, but a negative test is not enough to exclude an endometriosis diagnosis with full certainty. The review, “Diagnostic accuracy ... Read more

October 21, 2016October 26, 2016

Improved Quality of Life Reported by Endometriosis Patients Treated with Elagolix in Study

News

Drawing on data from two large Phase 3 clinical trials of endometriosis-related pain, AbbVie demonstrated that its oral drug candidate elagolix (ABT-620) improved patients’ impressions of pain as well as ... Read more

October 20, 2016October 20, 2016

Health Risks and Healthcare Costs of Endometriosis Detailed in AbbVie Report at ASRM

News

AbbVie recently presented two posters at the 72nd American Society for Reproductive Medicine Scientific Congress & Expo (ASRM) that highlighted the many comorbidities, or related conditions, faced by women with endometriosis, as well as the economic ... Read more

October 19, 2016October 20, 2016

Pain of Endometriosis Eased by Elagolix Without Severe Bone Loss in Phase 3 Study, AbbVie Reports

News

In the largest endometriosis trials to date, AbbVie demonstrated that the elagolix (ABT-620), an oral drug now in Phase 3 clinical testing, is not only effective in managing endometriosis-related pain, ... Read more

October 17, 2016

Study Finds Anti-platelet Therapy Useful in Mice with Endometrial Disorder Adenomyosis

News

Researchers from several Chinese institutions conducted a mouse study and found that anti-platelet therapy could be used as an efficient treatment for adenomyosis, an endometrial condition present in some endometriosis patients. ... Read more

October 13, 2016October 13, 2016

AbbVie to Present Important Data on Endometriosis Therapy Elagolix, and Economic Burden of Disease

News

Global biopharmaceutical AbbVie, in collaboration with Neurocrine Biosciences, will present five posters and three oral presentations next week from two Phase 3 studies on Elagolix, their investigational drug for endometriosis. The 72nd American ... Read more

October 12, 2016October 12, 2016

Formation of New Blood Vessels Accompanies Progression of Ovarian Endometriosis

News

Ovarian endometriosis is associated with increased levels of molecular factors that stimulate the pathological formation of new blood vessels that support the endometriomas, according to a new study. The study, ... Read more